Deforolimus

From Wikipedia, the free encyclopedia

Deforolimus (also known as AP23573 and MK-8669) is an immunosupressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

Deforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008, a phase III clinical trial of deforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients.[1][2]

[edit] References

  1. ^ SUCCEED: Landmark Global Phase 3 Trial Now Enrolling!. ARIAD Pharmaceuticals (2008). Retrieved on 2008-04-18.
  2. ^ Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study. ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.

[edit] External links

Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.